Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.025
-0.025 (-2.38%)
Sep 4, 2025, 12:07 PM - Market open
Ocugen Employees
Ocugen had 95 employees as of December 31, 2024. The number of employees increased by 30 or 46.15% compared to the previous year.
Employees
95
Change (1Y)
30
Growth (1Y)
46.15%
Revenue / Employee
$50,042
Profits / Employee
-$599,853
Market Cap
320.11M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 95 | 30 | 46.15% |
| Dec 31, 2023 | 65 | -19 | -22.62% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 41 | 273.33% |
| Dec 31, 2020 | 15 | -1 | -6.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OCGN News
- 2 days ago - Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 - GlobeNewsWire
- 22 days ago - Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - GlobeNewsWire
- 22 days ago - Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - GlobeNewsWire
- 26 days ago - Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - GlobeNewsWire
- 4 weeks ago - Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Ocugen Provides Business Update with Second Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team - GlobeNewsWire
- 6 weeks ago - Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease - GlobeNewsWire